0.93
0.93 (0%)
As of Feb 14, 2025
Tempest Therapeutics, Inc. [TPST]
Source:
Company Overview
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company moving towards late-stage development with a diverse portfolio of targeted and immune-mediated product candidates with the potential to be first-in-class to treat a wide range of cancers.
| Country | United States |
| Headquarters | brisbane, california |
| Phone Number | (415) 798-8589 |
| Industry | manufacturing |
| CEO | Stephen Brady |
| Website | clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-42 |
| Net Income | $-41.8 |
| Net Cash | $-9 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -89.9% |
| Profit as % of Stockholder Equity | -218.8% |
Management Effectiveness
| Return on Equity | -218.8% |
| Return on Assets | -100.9% |
| Turnover Ratio | |
| EBITA | $-42 |
Balance Sheet and Cash Flow Measures
| Total Assets | $41.5 |
| Total Liabilities | $22.4 |
| Operating Cash Flow | $-33 |
| Investing Cash Flow | $-0.4 |
| Financing Cash Flow | $24.5 |
